Skip to content

Site logo

Main menu
  • Company
    • Company overview
    • Stories
    • History
    • Environmental, Social & Governance (ESG)
      • ESG overview
      • Philanthropy
      • Merck Medical Outreach Program
      • Impact investing
      • Transparency disclosures
      • ESG resources
    • Leadership
      • Leadership overview
      • Board of directors
      • Executive team
    • Culture & values
      • Culture & values overview
      • Code of conduct & compliance
    • Diversity & inclusion
    • Policies & positions
    • Business development & licensing
    • Suppliers
      • Suppliers overview
      • Supplier registration
      • Supplier help for Ariba
  • Research
    • Research overview
    • Areas of focus
      • Oncology
      • Vaccines
      • Infectious diseases
      • Cardio-metabolic disorders
    • Pipeline
    • Discovery & development
    • R&D locations
    • Clinical trials
      • Clinical trials overview
      • Find a trial
      • Diversity in clinical trials
  • Products
    • Products list
    • Safety data sheets
    • Product patents
    • Merck authorized distributors
  • Patients
    • Patients overview
    • Patient support programs
    • Patient resources
    • Patient & treatment education
  • Careers
    • Careers
    • Search jobs
    • Our divisions
      • Research & development
      • Manufacturing & supply
      • Human Health
      • Animal Health
      • Global support functions
    • Veterans
    • Student opportunities
    • Compensation & benefits
    • How we hire
    • MSD Careers
    • Events
    • Talent community
  • Investors
    • Investors overview
    • Events & presentations
    • Financial information
      • Financial information overview
      • SEC filings
    • Stock information
    • Investor resources
      • Investor resources overview
      • Organon resources
      • Request for information
  • Media
    • Media overview
    • News releases
    • Company statements
    • Media library & contacts
    • Company fact sheet
two scientists wearing masks

Our COVID-19 efforts

Learn more
Contact us

Worldwide Countries outside of the United States and Canada.

What can we help you find?

Search for:
Environmental, Social & Governance

Meet the inaugural Health Equity Catalyst Fund initiatives

Teams around the world will put new funding to good use helping address urgent global needs

September 9, 2022

Share this article

a nurse talking with a pregnant woman

Over the past two years, COVID-19 has highlighted cracks in health care systems that are leaving the most vulnerable behind. That’s why our Social Business Innovation group’s health equity team launched the Health Equity Catalyst Fund and put out a call for employees to pitch ideas to help address urgent global health needs.  

After an arduous submission and review process, teams across the Merck world were ecstatic when they found out their initiatives would move ahead with support from the $1 million fund. Watch as we reveal the good news: 

Watch the video

health equity nominations

A catalyst for change 

The $1 million Health Equity Catalyst Fund empowers local teams to help improve equitable health outcomes by engaging at the community level to remove barriers to care and/or by strengthening health systems to deliver on high-quality and accountable care. The fund will support 15 initiative across 13 countries in regions with high unmet needs and the potential for significant population health impact.

“Our company has a long legacy of helping to address the social determinants of health, and we’ve always taken on society’s most urgent health challenges motivated by our purpose of helping save and improve lives,” said Carmen Villar, VP of social business innovation. “The Health Equity Catalyst Fund provides another opportunity for us to take an all-company approach to advance health equity at both the global and local levels.” 

The selected initiatives focus on a variety of themes and priorities, including community-based vaccination support, bringing cancer screenings into communities, helping patients with transportation barriers and much more.   

As the fund’s 15 initiatives move forward, they’ll serve as great examples of how Merck can win as one team, collaborate and innovate to advance health equity. 

Discover more stories

New podcast: Meet the dealmakers 

Safeguarding the environment through green chemistry

One scientist’s commitment to dengue fever research

View all stories

Explore more in

Collaboration
Corporate responsibility
Our people

Related links

related content image #1

Our culture and values

It all comes back to saving and improving lives

related content image #2

Environmental, Social & Governance (ESG)

Supporting society, people and communities around the world is fundamental to our long-term success

related content image #3

Diversity & inclusion

Our workforce represents the people we serve

Connect with us on social

social icon social icon social icon social icon social icon
  • MerckHelps
    Merck Patient Assistance Program provides certain Merck medicines and adult vaccines for free to qualified patients
  • Merck Access Program
    Information about insurance coverage and financial assistance options for eligible patients
  • Clinical trials
    Learn about our clinical trials and find available studies
  • Merck Manuals
    Medical information source covering thousands of topics in all fields of medicine
  • Environmental, Social & Governance (ESG) Report
    Reporting on our commitment to operating responsibly to benefit society
  • Merck for Mothers
    An initiative to create a world where no woman has to die giving life
  • Merck Animal Health
    The global animal health business unit of Merck
  • Health Plan - Transparency in Coverage
    In compliance with the Consolidated Appropriations Act, learn more about our health plan's pricing information.
  • Forward-looking statement
  • Cookie policy
  • Privacy
  • Transparency disclosure
  • Terms of use
  • Accessibility
  • Sitemap
Copyright © 2023 Merck & Co., Inc., Rahway, NJ USA, and its affiliates. All rights reserved. | This site is intended only for residents of the United States and Canada.
Accessibility icon View Privacy Shield Verification Status View APEC CBPR Privacy Certification Status

Forward-looking statement of Merck & Co., Inc., Rahway, N.J., USA

This website of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2022 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

No Duty to Update
The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.

Decline Accept

You are leaving Merck.com

Continue

Welcome to Merck.com

By continuing, you will be directed to a site intended only for residents of the United States and Canada. We are called MSD everywhere, except in the United States and Canada where we are known as Merck & Co Inc, Rahway, NJ USA.

Continue